Evidence map›Paper›PMID 27677884›Full record

ArticleClinical and experimental nephrology2017

Recurrence and graft loss after renal transplantation in adults with IgA vasculitis.

Mayuko Kawabe, Izumi Yamamoto, Yo Komatsuzaki, Takafumi Yamakawa, Haruki Katsumata, Ai Katsuma, Aki Mafune, Yasuyuki Nakada, Akimitsu Kobayashi, Yudo Tanno and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Mayuko KawabeDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Izumi YamamotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan. izumi26@jikei.ac.jp.
Yo KomatsuzakiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Takafumi YamakawaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Haruki KatsumataDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Ai KatsumaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Aki MafuneDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Yasuyuki NakadaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Akimitsu KobayashiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Yudo TannoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Ichiro OhkidoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Nobuo TsuboiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Keitaro YokoyamaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Shigeru HoritaDepartment of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
Masayoshi OkumiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Hideki IshidaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Hiroyasu YamamotoDepartment of Internal Medicine, Atsugi City Hospital, Kanagawa, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, 105-8461, Tokyo, Japan.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Japan Academic Consortium of Kidney Transplantation (JACK)
Jikei University School of Medicine · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIgA vasculitis, a rare condition resulting in end-stage renal disease, is a small-vessel vasculitis that affects the kidney in 49-83 % of adults. The reported recurrence rate of IgA vasculitis in renal transplant recipients is 11.5-60 %, leading to graft loss in 0-50 % of these patients. However, limited data are available on recurrence and graft loss after renal transplantation.

methodsWe evaluated renal transplant recipients seen from 1987 to 2015 at the Jikei University School of Medicine and the Department of Urology, Tokyo Women's Medical University. Using a 1:2 match, 21 patients with IgA vasculitis and 42 controls were selected. The mean post-transplant follow-up was 121 ± 69 months for IgA vasculitis and 147 ± 66 months for the controls.

resultsThe 15-year patient survival was 100 % in IgA vasculitis and 97.6 % in the controls (p = 0.22). The 5-, 10-, and 15-year graft survival rates were 95.2, 90.5, and 81 % in IgA vasculitis and 100, 90.5, and 88.1 % in the controls, respectively (p = 0.63). The recurrence rate was 28.6 % (6 of 21 cases) and half of them (3 of 6 cases) showed histological activity (ISKDC III). We treated them with methylprednisolone pulse therapy and/or tonsillectomy. None of the recurrence cases lost the allograft.

conclusionThe long-term patient and graft survival of IgA vasculitis in renal transplantation were comparable with the previous reports. The recurrence rate was 28.6 %, but none of the recurrent cases showed allograft loss in this study. We speculate that methylprednisolone pulse therapy and/or tonsillectomy prevent the progression of recurrent IgA vasculitis.

Indexed as

Graft SurvivalAdultAllograftsFemaleHumansImmunoglobulin AImmunosuppressive AgentsKaplan-Meier EstimateKidney Failure, ChronicKidney TransplantationMaleMethylprednisolonePulse Therapy, DrugRecurrenceRetrospective StudiesRisk FactorsImmunoglobulin AImmunosuppressive AgentsMethylprednisoloneIgA vasculitisKidney transplantationRecurrence of kidney diseaseTonsillectomy

Identifiers

PMID27677884
OpenAlexW2526033204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.